Literature DB >> 7648722

Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.

A D Roth1, S Dupuis, P Alberto.   

Abstract

As IL-4 and IL-6 have also been reported to promote the development of T lymphocytes such as IL-2, we investigated their role in the development of specific cytotoxic T lymphocytes (CTL) against autologous ovarian tumours in mixed lymphocyte tumour cultures (MLTC). Peripheral blood lymphocytes (PBL) from five ovarian carcinoma (OC) patients were incubated with autologous OC cells at a PBL:OC cell ratio of 20:1 in IL-2 alone (50 U/ml for the first week and 200 U/ml thereafter) or with IL-4 (100 U/ml) and/or IL-6 (5 U/ml). Neither IL-4 nor IL-6 improved lymphocyte proliferation consistently. In contrast, IL-4 reduced significantly the development of LAK activity as assayed against Daudi cell line, and decreased modestly the emergence of natural killer (NK) activity as assayed against K562. This property was not shared by IL-6. The prevention of the development of non-specific cytolytic activity (LAK and NK activities) was much stronger when the MLTC was started with IL-4 in the absence of IL-2 during the first week in culture. A concomitant drop in NKH-1 expression (CD56) was observed. By inhibiting the emergence of non-specific cytotoxicity, IL-4 provided better evidence of the specific cytolytic activity directed at ovarian cells. In parallel, a significant increase in the generation of memory cells (CD4+CD45RO+) was observed with IL-4. In conclusion, in this model, IL-4 added before IL-2 decreases significantly the emergence of non-specific cytotoxic cells, and promotes the generation of memory cells. These properties may be of interest in the design of strategies aimed at obtaining tumour-specific cells for investigational and immunotherapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648722      PMCID: PMC1553279          DOI: 10.1111/j.1365-2249.1995.tb08365.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma.

Authors:  G Fossati; A Anichini; P Squarcina; A Mazzocchi; G Parmiani
Journal:  Int J Cancer       Date:  1988-08-15       Impact factor: 7.396

2.  The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation.

Authors:  A Nagler; L L Lanier; J H Phillips
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

3.  Miniaturization of the standard 51Cr release assay for long term follow-up of NK activity of individual mice.

Authors:  I Yron; L Shohat
Journal:  J Immunol Methods       Date:  1986-11-06       Impact factor: 2.303

4.  IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.

Authors:  S D Colquhoun; J S Economou; H Shau; S H Golub
Journal:  J Surg Res       Date:  1993-11       Impact factor: 2.192

5.  Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors.

Authors:  F Erard; P Corthesy; M Nabholz; J W Lowenthal; P Zaech; G Plaetinck; H R MacDonald
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

6.  Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.

Authors:  S Miescher; T L Whiteside; S Carrel; V von Fliedner
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

7.  Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors:  M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

8.  A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.

Authors:  R J Melder; T L Whiteside; N L Vujanovic; J C Hiserodt; R B Herberman
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

9.  Long-term culture of human antigen-specific cytotoxic T-cell lines.

Authors:  S Gillis; P E Baker; F W Ruscetti; K A Smith
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

10.  Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.

Authors:  J J Mulé; C A Smith; S A Rosenberg
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

View more
  1 in total

1.  Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.

Authors:  K Matsunaga; M Nakao; K Masuoka; Y Inoue; R Gouhara; T Imaizumi; S Nishizaka; K Itoh
Journal:  Jpn J Cancer Res       Date:  1999-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.